EA202090821A1 - A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC - Google Patents
A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLCInfo
- Publication number
- EA202090821A1 EA202090821A1 EA202090821A EA202090821A EA202090821A1 EA 202090821 A1 EA202090821 A1 EA 202090821A1 EA 202090821 A EA202090821 A EA 202090821A EA 202090821 A EA202090821 A EA 202090821A EA 202090821 A1 EA202090821 A1 EA 202090821A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tumors
- present
- tumor
- relates
- immunotherapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 230000005975 antitumor immune response Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к пептидам, нуклеиновым кислотам и клеткам для применения в иммунотерапевтических методах. В частности, настоящее изобретение относится к иммунотерапии рака. Настоящее изобретение относится далее к опухолеассоциированным цитотоксическим пептидным эпитопам Т-клеток (ЦТЛ), в отдельности или в комбинации с другими опухолеассоциированными пептидами, которые служат в качестве активных фармацевтических ингредиентов вакцинных композиций, стимулирующих противопухолевые иммунные ответы. Настоящее изобретение относится к более чем 70 новым пептидным последовательностям и их вариантам, образованным из молекул HLA класса I и HLA класса II человеческих опухолевых клеток, которые могут быть использованы в вакцинных композициях для вызывания противоопухолевых иммунных ответов.The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to tumor-associated cytotoxic T-cell peptide epitopes (CTLs), alone or in combination with other tumor-associated peptides, which serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and variants thereof derived from HLA class I and HLA class II human tumor cell molecules that can be used in vaccine compositions to elicit antitumor immune responses.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1403297.3A GB201403297D0 (en) | 2014-02-25 | 2014-02-25 | Novel immunotherapy against several tumors, such as lung cancer, including NSCLC |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090821A1 true EA202090821A1 (en) | 2020-12-30 |
Family
ID=50482767
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090816A EA202090816A3 (en) | 2014-02-25 | 2014-08-04 | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC |
| EA202090822A EA202090822A3 (en) | 2014-02-25 | 2014-08-04 | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC |
| EA202090821A EA202090821A1 (en) | 2014-02-25 | 2014-08-04 | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090816A EA202090816A3 (en) | 2014-02-25 | 2014-08-04 | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC |
| EA202090822A EA202090822A3 (en) | 2014-02-25 | 2014-08-04 | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC |
Country Status (2)
| Country | Link |
|---|---|
| EA (3) | EA202090816A3 (en) |
| GB (1) | GB201403297D0 (en) |
-
2014
- 2014-02-25 GB GBGB1403297.3A patent/GB201403297D0/en not_active Ceased
- 2014-08-04 EA EA202090816A patent/EA202090816A3/en unknown
- 2014-08-04 EA EA202090822A patent/EA202090822A3/en unknown
- 2014-08-04 EA EA202090821A patent/EA202090821A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202090822A2 (en) | 2020-07-31 |
| EA202090822A3 (en) | 2020-08-31 |
| EA202090816A2 (en) | 2020-07-31 |
| GB201403297D0 (en) | 2014-04-09 |
| EA202090816A3 (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690016A1 (en) | NEW IMMUNOTHERAPY METHOD FOR MULTIPLE TUMOR SPECIES, SUCH AS LUNG CANCER, INCLUDING NSCLC | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| EA202090751A3 (en) | A NEW METHOD OF IMMUNOTHERAPY OF SEVERAL TYPES OF TUMOR BLOOD DISEASES SUCH AS Acute Myeloid Leukemia (AML) | |
| EP3708185A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| SG10201900727QA (en) | Personalized immunotherapy against several neuronal and brain tumors | |
| EA202091242A3 (en) | NEW METHODS OF IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS, INCLUDING GASTROINTESTINAL CANCER AND STOMACH CANCER | |
| EA201071297A1 (en) | NEW AND EFFECTIVE PEPTIDES OF THE MHC II CLASS RECEIVED FROM Survivin | |
| PH12016502008A1 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml) | |
| EA202090821A1 (en) | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
| MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| EA201990696A1 (en) | PERSONALIZED IMMUNOTHERAPY OF SEVERAL SPECIES OF NEURAL TUMORS AND BRAIN TUMORS | |
| MX2019013161A (en) | Personalized immunotherapy against several neuronal and brain tumors. |